Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Trastuzumab Rezetecan in Triple Negative Breast Cancer: NCT05749588 Clinical Landscape Report 2026
16 October 2026
NCT05749588 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Metastatic breast cancer: NCT05756166 Clinical Landscape Report 2026
16 October 2026
NCT05756166 clinical landscape for Metastatic breast cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Eribulin mesylate in Triple Negative Breast Cancer: NCT05760378 Clinical Landscape Report 2026
16 October 2026
NCT05760378 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
OATD-02 in Metastatic Renal Cell Carcinoma: NCT05759923 Clinical Landscape Report 2026
16 October 2026
NCT05759923 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zedoresertib in Glioblastoma, IDH-Wildtype: NCT05765812 Clinical Landscape Report 2026
16 October 2026
NCT05765812 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in Renal Medullary Carcinoma: NCT05768464 Clinical Landscape Report 2026
16 October 2026
NCT05768464 clinical landscape for Renal Medullary Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sacituzumab govitecan-hziy in HER2-negative breast cancer: NCT05770531 Clinical Landscape Report 2026
16 October 2026
NCT05770531 clinical landscape for HER2-negative breast cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RO-7515629 in Pancreatic adenocarcinoma: NCT05769959 Clinical Landscape Report 2026
16 October 2026
NCT05769959 clinical landscape for Pancreatic adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma Multiforme: NCT05769660 Clinical Landscape Report 2026
16 October 2026
NCT05769660 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tislelizumab in Advanced Malignant Solid Neoplasm: NCT05768932 Clinical Landscape Report 2026
16 October 2026
NCT05768932 clinical landscape for Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Temsirolimus in Glioblastoma: NCT05773326 Clinical Landscape Report 2026
16 October 2026
NCT05773326 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Azeliragon in Glioblastoma: NCT05773664 Clinical Landscape Report 2026
16 October 2026
NCT05773664 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.